Indeed, meta-analysis in randomized clinical trials of anti-PD-1/PD-L1 therapy (atezolizumab, pembrolizumab, and nivolumab) demonstrated the efficacy and safety and could dramatically improve the PFS and OS compared with docetaxel for patients with previously treated NSCLC [56, 57] and enhance the PFS and OS compared to EGFR-TKI alone for NSCLC patients with EGFR wild type [56]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.